Skip to main content
Sign In

Eamon Berge, M.D.

Assistant Professor, Division of Medical Oncology

Dr. Berge joined the University of Colorado School of Medicine faculty as an Assistant Professor in 2013. He trained in Internal Medicine at the University of Colorado with subsequent Fellowship Training at the University of Colorado in Hematology/Medical Oncology.
Clinical Interests/Research
Dr. Berge provides care to patients with solid tumors and benign/malignant hematology conditions at the University of Colorado’s satellite facility in Lone Tree, Colorado. In addition, he is involved in clinical research, multidisciplinary clinics, and tumor board review through the Thoracic Malignancies program and the Breast Oncology program at the University of Colorado.
Selected Publications
Berge, E, Thompson, C, Messersmith, W. Development of Novel Targeted Agents in the Treatment of Metastatic Colon Cancer. Clin Colorectal Cancer 2011 Dec 10(4):266-78. PMID:21903484
Doebele, RC, Aisner, DL, Le, AT, Berge, EM, Pilling, AB, Kutateladze, TG Resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. 2012 ASCO Annual Meeting (Chicago, IL). Abstract #97201
Moran, DM, Trusk, P, Shell, AS, Camidge, DR, Doebele, RC, Berge, EM Vincent, M, Bacus, S.  KRAS mutation and amplification status predicts sensitivity to antifolate therapies in Non-Small Cell Lung Cancer. 2012 AACR Annual Meeting (Chicago, IL) Abstract # LB-449
Davies, KD, Le , AT, Theodoro, MF, Skokan,  MC, Aisner, DL,  Berge, EM, Terracciano, LM, Cappuzzo, F, Incarbone,  M, Roncalli, M, Alloisio, M, Santoro, A, Camidge, DR, Varella-Garcia, M, Doebele, RC. Identifying and targeting ROS1 gene gusions in Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Sep 1;18(17):4570-9. PMID: 22919003
Berge EM, Doebele RC. Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs. 2013 May;73(6):517-32 PMID: 23591906
Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May;49(5):303-15. PMID: 23724410
Varella-Garcia M, Xu LG, Mahale S, Berge EM, Bennati C, Le AT, Aisner DL, Crinò L, Bunn PA, Camidge   DR, Doebele RC. RET rearrangements detected by FISH in ‘pan-negative’ lung adenocarcinoma. J Clin Oncol 2013 ASCO Ann Meeting Proc. Vol 31, No 15, 2013: 8024
Berge EM, Lu X, Maxson D, Barón AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M, Camidge DR. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013 Nov;14(6):636-43. PMID: 23931899
Berge EM, Aisner DL, Doebele RC. Erlotinib response in an NSCLC Patient with a novel compound G719D+L861R  mutation in EGFR.  J Thorac Oncol. 2013 Sep;8(9):e83-4. PMID:23945392
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park SI, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013 Nov;19(11):1469-72. PMID: 24162815